Expression of prostate specific molecules in Bacille Calmette-Guerin: An immunotherapeutic approach to prostate cancer

C. D. Zeoli, M. Maitland, H. Rose, B. Bloom, A. Mittelman, J. Geliebter

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The objective is to develop an immunotherapeutic vaccine for the treatment of metastatic prostate cancer. Results: Bacille Calmette Guerin (BCG) were engineered to express prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA). Western blotting techniques indicate that recombinant BCG (rBCG) express approximately 25 ng PSA or 112 pg PSMA per 1 μg microgram of protein in rBCG bacterial lysates. Discussion: BCG, the vaccine for tuberculosis, is a potent immunologic adjuvant stimulating both the humoral and cell-mediated immune systems. Prostate cancer patients can generate cytotoxic lymphocytes against specific peptides from normal, self-molecules such as PSA and PSMA. Therefore, a rBCG vaccine that expresses prostate specific proteins may stimulate an immune response to recognize and destroy prostate cancer cells. Conclusion: BCG can be engineered to express prostate specific molecules and may be useful as an immunotherapeutic vaccine against prostate cancer.

Original languageEnglish (US)
Pages (from-to)92-97
Number of pages6
JournalProstate Journal
Volume3
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Prostate
Prostatic Neoplasms
Prostate-Specific Antigen
BCG Vaccine
Vaccines
Immunologic Adjuvants
Synthetic Vaccines
Mycobacterium bovis
Recombinant Proteins
Immune System
Tuberculosis
Western Blotting
Lymphocytes
Peptides
human glutamate carboxypeptidase II
Proteins
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

Expression of prostate specific molecules in Bacille Calmette-Guerin : An immunotherapeutic approach to prostate cancer. / Zeoli, C. D.; Maitland, M.; Rose, H.; Bloom, B.; Mittelman, A.; Geliebter, J.

In: Prostate Journal, Vol. 3, No. 2, 2001, p. 92-97.

Research output: Contribution to journalArticle

Zeoli, C. D. ; Maitland, M. ; Rose, H. ; Bloom, B. ; Mittelman, A. ; Geliebter, J. / Expression of prostate specific molecules in Bacille Calmette-Guerin : An immunotherapeutic approach to prostate cancer. In: Prostate Journal. 2001 ; Vol. 3, No. 2. pp. 92-97.
@article{3b5ae1e9e65246ba956c9a89f060080b,
title = "Expression of prostate specific molecules in Bacille Calmette-Guerin: An immunotherapeutic approach to prostate cancer",
abstract = "Objective: The objective is to develop an immunotherapeutic vaccine for the treatment of metastatic prostate cancer. Results: Bacille Calmette Guerin (BCG) were engineered to express prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA). Western blotting techniques indicate that recombinant BCG (rBCG) express approximately 25 ng PSA or 112 pg PSMA per 1 μg microgram of protein in rBCG bacterial lysates. Discussion: BCG, the vaccine for tuberculosis, is a potent immunologic adjuvant stimulating both the humoral and cell-mediated immune systems. Prostate cancer patients can generate cytotoxic lymphocytes against specific peptides from normal, self-molecules such as PSA and PSMA. Therefore, a rBCG vaccine that expresses prostate specific proteins may stimulate an immune response to recognize and destroy prostate cancer cells. Conclusion: BCG can be engineered to express prostate specific molecules and may be useful as an immunotherapeutic vaccine against prostate cancer.",
author = "Zeoli, {C. D.} and M. Maitland and H. Rose and B. Bloom and A. Mittelman and J. Geliebter",
year = "2001",
doi = "10.1046/j.1525-1411.2001.32002.x",
language = "English (US)",
volume = "3",
pages = "92--97",
journal = "Prostate Journal",
issn = "1095-5100",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Expression of prostate specific molecules in Bacille Calmette-Guerin

T2 - An immunotherapeutic approach to prostate cancer

AU - Zeoli, C. D.

AU - Maitland, M.

AU - Rose, H.

AU - Bloom, B.

AU - Mittelman, A.

AU - Geliebter, J.

PY - 2001

Y1 - 2001

N2 - Objective: The objective is to develop an immunotherapeutic vaccine for the treatment of metastatic prostate cancer. Results: Bacille Calmette Guerin (BCG) were engineered to express prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA). Western blotting techniques indicate that recombinant BCG (rBCG) express approximately 25 ng PSA or 112 pg PSMA per 1 μg microgram of protein in rBCG bacterial lysates. Discussion: BCG, the vaccine for tuberculosis, is a potent immunologic adjuvant stimulating both the humoral and cell-mediated immune systems. Prostate cancer patients can generate cytotoxic lymphocytes against specific peptides from normal, self-molecules such as PSA and PSMA. Therefore, a rBCG vaccine that expresses prostate specific proteins may stimulate an immune response to recognize and destroy prostate cancer cells. Conclusion: BCG can be engineered to express prostate specific molecules and may be useful as an immunotherapeutic vaccine against prostate cancer.

AB - Objective: The objective is to develop an immunotherapeutic vaccine for the treatment of metastatic prostate cancer. Results: Bacille Calmette Guerin (BCG) were engineered to express prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA). Western blotting techniques indicate that recombinant BCG (rBCG) express approximately 25 ng PSA or 112 pg PSMA per 1 μg microgram of protein in rBCG bacterial lysates. Discussion: BCG, the vaccine for tuberculosis, is a potent immunologic adjuvant stimulating both the humoral and cell-mediated immune systems. Prostate cancer patients can generate cytotoxic lymphocytes against specific peptides from normal, self-molecules such as PSA and PSMA. Therefore, a rBCG vaccine that expresses prostate specific proteins may stimulate an immune response to recognize and destroy prostate cancer cells. Conclusion: BCG can be engineered to express prostate specific molecules and may be useful as an immunotherapeutic vaccine against prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0035715916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035715916&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1411.2001.32002.x

DO - 10.1046/j.1525-1411.2001.32002.x

M3 - Article

AN - SCOPUS:0035715916

VL - 3

SP - 92

EP - 97

JO - Prostate Journal

JF - Prostate Journal

SN - 1095-5100

IS - 2

ER -